Internal Medicine

Data from 5 trials presented at ID Week 2021 are promising for the investigational biotherapeutic.

Adult patients with moderate-to-severe atopic dermatitis reported incremental improvement of their condition in a new extension trial study presented at EADV.

Investigators reported that the vaccine prevented symptomatic and severe cases of COVID-19 in several populations including older patients.

Maralixibat oral solution is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.

The mean number of injections per year was 6.2 ± 1.4 injections following 1 year of treatment in 2007 - 2010 and 8.3 ± 2.0 injections in 2016 - 2017.

Investigators reported that the drug helped improve skin repigmentation in patients with vitiligo, but added that further studies were needed to fully explore its efficacy.

Investigators believed the immunosuppressive qualities of these biologics posed no additional risk in contracting the COVID-19 virus, but added that additional research is warranted.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Acknowledging the potential medical harm from errors and bias, investigators believe clinical AI needs to be held to a higher standard.

Patients with pediatric solid tumors and hematological malignancies were more prone to C difficile infections.

Baseline VA show slight improvement in aflibercept versus ranibizumab treated eyes, (42.5 letters versus 36.9 letters).

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

A Cleveland Clinic trial assessing the effects of 3 healthy eating patterns in children with overweight or obesity details the improvements in cardiovascular risk factors seen with adherence to a healthy eating pattern.

In his recent presentation, Dr. Sperling spoke of how a greater focus needed to be made on the implementation of cardiovascular care strategies, as well as better utilization of health system approaches.

The risk of TB was 48% higher in patients with diabetes compared to those without diabetes, while participants with IFG showed no increased risk of TB incidence.

Students who received eyeglasses through a school-based vision program achieved better reading scores, but sustained impact not observed after 2 years.

Incidence of myopia was 7.9% higher in the exposure group, compared to the non-exposure group from grade 2 to grade 3.

The approval of ranibizumab-nuna marks the first ophthalmology biosimilar to become FDA approved in the United States.

Though well-tolerated and highly efficacious, the biologic was linked several adverse events in pediatric patients with atopic dermatitis including facial erythema and herpes simplex virus.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

The new PDUFA date for Nefecon will be December 15, 2021.

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.